BIOLOGÍA MOLECULAR Y CELULAR EN HEMOPATÍAS
Hospital Universitario Central de Asturias
Oviedo, EspañaPublicaciones en colaboración con investigadores/as de Hospital Universitario Central de Asturias (62)
2023
-
Baseline immunophenotypic profile of bone marrow leukemia cells in acute myeloid leukemia with nucleophosmin-1 gene mutation: a EuroFlow study
Blood Cancer Journal
-
Comparison of the 2022 and 2017 European LeukemiaNet risk classifications in a real-life cohort of the PETHEMA group
Blood Cancer Journal, Vol. 13, Núm. 1
-
IGLV3-21R110 mutation has prognostic value in patients with treatment-naive chronic lymphocytic leukemia
Blood Advances
-
Impact of pre- and/or post-autologous stem cell transplantation exposure to brentuximab vedotin on survival outcomes in patients with high-risk Hodgkin lymphoma
Annals of Hematology, Vol. 102, Núm. 2, pp. 429-437
-
Integrated flow cytometry and sequencing to reconstruct evolutionary patterns from dysplasia to acute myeloid leukemia
Blood Advances, Vol. 7, Núm. 1, pp. 167-173
-
Molecular Landscape and Validation of New Genomic Classification in 2668 Adult AML Patients: Real Life Data from the PETHEMA Registry
Cancers, Vol. 15, Núm. 2
-
Prognostic Value of Measurable Residual Disease in Patients with AML Undergoing HSCT: A Multicenter Study
Cancers, Vol. 15, Núm. 5
2022
-
Characteristics and Outcomes of Adult Patients in the PETHEMA Registry with Relapsed or Refractory FLT3-ITD Mutation-Positive Acute Myeloid Leukemia
Cancers, Vol. 14, Núm. 11
-
Impact of FLT3–ITD Mutation Status and Its Ratio in a Cohort of 2901 Patients Undergoing Upfront Intensive Chemotherapy: A PETHEMA Registry Study
Cancers, Vol. 14, Núm. 23
2021
-
Evolving treatment patterns and outcomes in older patients (≥60 years) with AML: changing everything to change nothing?
Leukemia, Vol. 35, Núm. 6, pp. 1571-1585
-
Impact of measurable residual disease by decentralized flow cytometry: a PETHEMA real-world study in 1076 patients with acute myeloid leukemia
Leukemia, Vol. 35, Núm. 8, pp. 2358-2370
2020
-
Corrigendum to “Performance of prognostic scoring systems in elderly patients with acute myeloid leukaemia on intensive chemotherapy: A PETHEMA registry study” [Leuk. Res. 92 (March) (2020) 06352] (Leukemia Research (2020) 92, (S0145212620300576), (10.1016/j.leukres.2020.106352))
Leukemia Research
-
Genomic analysis of a familial myelodysplasia/acute myeloid leukemia and inherited RUNX1 mutations without a pre-existing platelet disorder
Leukemia and Lymphoma
-
Networking for advanced molecular diagnosis in acute myeloid leukemia patients is possible: the PETHEMA NGS-AML project
Haematologica, Vol. Online ahead of print
-
Performance of prognostic scoring systems in elderly patients with acute myeloid leukaemia on intensive chemotherapy: A PETHEMA registry study
Leukemia Research, Vol. 92
-
Reply to Brown et al: ‘Correct application of variant classification guidelines in germline RUNX1 mutated disorders to assist clinical diagnosis’
Leukemia and Lymphoma
2019
-
Brentuximab vedotin and ESHAP is highly effective as second-line therapy for Hodgkin lymphoma patients (long-term results of a trial by the Spanish GELTAMO Group)
Annals of Oncology, Vol. 30, Núm. 4, pp. 612-620
-
Exportin-1 E571K mutation is a common finding in patients with classical Hodgkin lymphoma
Hematological Oncology
2018
-
The mutational landscape of small lymphocytic lymphoma compared to non-early stage chronic lymphocytic leukemia
Leukemia and Lymphoma, Vol. 59, Núm. 10, pp. 2318-2326
2017
-
Update of the Grupo Español de Leucemia Linfocítica Crónica clinical guidelines of the management of chronic lymphocytic leukemia
Medicina Clinica, Vol. 148, Núm. 8, pp. 381.e1-381.e9